All Stories

  1. Brain Changes in Treatment Resistant Depression
  2. Relief from Major Depression with electrical stimulation
  3. Deep Brain Stimulation for Psychiatric and Neurological disorders
  4. Stopping DBS leads to Depression Relapse
  5. S113. Unintended Discontinuation of Deep Brain Stimulation for Treatment-Resistant Depression: A Case Series
  6. Clinical Predictors of Response to Magnetic Seizure Therapy in Depression
  7. Deep brain stimulation of the supero-lateral branch of the medial forebrain bundle does not lead to changes in personality in patients suffering from severe depression
  8. Tractography-assisted deep brain stimulation of the superolateral branch of the medial forebrain bundle (slMFB DBS) in major depression
  9. The anatomy of the human medial forebrain bundle: Ventral tegmental area connections to reward-associated subcortical and frontal lobe regions
  10. Degree of Postictal Suppression Depends on Seizure Induction Time in Magnetic Seizure Therapy and Electroconvulsive Therapy
  11. Autonomy in Depressive Patients Undergoing DBS-Treatment: Informed Consent, Freedom of Will and DBS’ Potential to Restore It
  12. 722. How Can We Optimize DBS Studies for Psychiatric Indications? New Data on Quality of Life and Personality
  13. 719. Deep Brain Stimulation for Treatment Resistant Depression – Where Are We Coming From?
  14. Deep brain stimulation to the medial forebrain bundle for depression- long-term outcomes and a novel data analysis strategy
  15. Being open minded about neuromodulation trials: Finding success in our “failures”
  16. Walking away from depression-motor activity increases ratings of mood and incentive drive in patients with major depression
  17. The medial forebrain bundle as a target for deep brain stimulation for obsessive-compulsive disorder
  18. Arachnophobia alleviated by subthalamic nucleus stimulation for Parkinson’s disease
  19. Deep brain stimulation for treatment resistant bipolar disorder
  20. Update on Neuromodulation for Treatment-Resistant Depression
  21. Faculty of 1000 evaluation for EEG effects of ECT: implications for rTMS.
  22. Faculty of 1000 evaluation for Cerebral implants and Parkinson's disease: a unique form of biographical disruption?
  23. Faculty of 1000 evaluation for A coil design for transcranial magnetic stimulation of deep brain regions.
  24. Faculty of 1000 evaluation for Recent developments and current controversies in depression.
  25. Faculty of 1000 evaluation for Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission.
  26. Faculty of 1000 evaluation for Effectiveness of a second deep TMS in depression: a brief report.
  27. Faculty of 1000 evaluation for Response to deep TMS in depressive patients with previous electroconvulsive treatment.
  28. Faculty of 1000 evaluation for Translational principles of deep brain stimulation.
  29. Faculty of 1000 evaluation for Quantitative EEG during seizures induced by electroconvulsive therapy: relations to treatment modality and clinical features. I. Global analyses.
  30. Faculty of 1000 evaluation for Pilot study of the clinical and cognitive effects of high-frequency magnetic seizure therapy in major depressive disorder.
  31. Faculty of 1000 evaluation for Quantitative EEG during seizures induced by electroconvulsive therapy: relations to treatment modality and clinical features. II. Topographic analyses.
  32. Deep Brain Stimulation in Neurological and Psychiatric Disorders
  33. Deep Brain Stimulation for Major Depression—Steps on a Long and Winding Road
  34. The impact of Parkinson’s disease and subthalamic deep brain stimulation on reward processing
  35. Oxytocin Facilitates the Extinction of Conditioned Fear in Humans
  36. Neuromodulative Treatments for Bipolar Disorder
  37. Diminished appetitive startle modulation following targeted inhibition of prefrontal cortex
  38. Effects of Electroconvulsive Therapy and Magnetic Seizure Therapy on Acute Memory Retrieval
  39. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial
  40. Aberrant NMDA receptor DNA methylation detected by epigenome-wide analysis of hippocampus and prefrontal cortex in major depression
  41. Magnetic seizure therapy in treatment-resistant depression: clinical, neuropsychological and metabolic effects
  42. World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care
  43. Opposing effects of oxytocin on moral judgment in males and females
  44. Einfluss der Tiefen Hirnstimulation des Nucleus subthalamicus auf exekutive Funktionen bei Patienten mit idiopathischem Parkinson-Syndrom unter Berücksichtigung von Apathie, Depressivität und Stimmung
  45. Tiefe Hirnstimulation bei therapieresistenter Depression
  46. Affective Neuroscience Strategies for Understanding and Treating Depression
  47. An Oxytocin-Induced Facilitation of Neural and Emotional Responses to Social Touch Correlates Inversely with Autism Traits
  48. Psycho-Informatics: Big Data shaping modern psychometrics
  49. Bilateral bispectral index monitoring during and after electroconvulsive therapy compared with magnetic seizure therapy for treatment-resistant depression
  50. S.03.01 Neuromodulation for treatment of severe and resistant psychiatric disorders, state of the art
  51. Deep Brain Stimulation works for treatment resistant depression
  52. Faculty Opinions recommendation of Behavioral and neurobiological effects of deep brain stimulation in a mouse model of high anxiety- and depression-like behavior.
  53. Brain stimulation treatments for depression
  54. Tiefe Hirnstimulation in Neurologie und Psychiatrie
  55. Tiefe Hirnstimulation als mögliche Alternative bei therapieresistenten Depressionen
  56. Consensus on guidelines for stereotactic neurosurgery for psychiatric disorders
  57. Primary-process separation-distress (PANIC/GRIEF) and reward eagerness (SEEKING) processes in the ancestral genesis of depressive affect.
  58. Reply to: Medial Forebrain Bundle Stimulation—Speed Access to an Old or Entry into a New Depression Neurocircuit?
  59. Comparable seizure characteristics in magnetic seizure therapy and electroconvulsive therapy for major depression
  60. Neuromodulation for Treatment Resistant Depression: State of the Art and Recommendations for Clinical and Scientific Conduct
  61. Not too much reason for excitement: Deep Brain Stimulation for Anorexia Nervosa
  62. Nicotinic Acetylcholine Receptors Contribute to Learning-induced Metaplasticity in the Hippocampus
  63. Deep Brain Stimulation for Depression
  64. Faculty Opinions recommendation of Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons.
  65. Faculty of 1000 evaluation for Deep brain stimulation restores frontostriatal network activity in obsessive-compulsive disorder.
  66. The Role of Nonpharmacological Interventions in Treatment‐resistant Depression
  67. Deep brain stimulation for major depression
  68. Bipolare Störungen (ICD-10 F3)
  69. Ethische Bewertung der Methoden psychiatrischer Neuromodulation
  70. Sicherheits- und Nebenwirkungsprofil der EKT
  71. Neurobiologie der Anhedonie
  72. A neuromodulation experience registry for deep brain stimulation studies in psychiatric research: Rationale and recommendations for implementation
  73. Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease
  74. Fear Processing and Social Networking in the Absence of a Functional Amygdala
  75. Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care
  76. Long-Term Effects of Nucleus Accumbens Deep Brain Stimulation in Treatment-Resistant Depression: Evidence for Sustained Efficacy
  77. Faculty of 1000 evaluation for Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression.
  78. Escitalopram for the prevention of peginterferon alpha-2a- and ribavirin-associated depression in HCV-infected patients without prior psychiatric disease: A randomized controlled trial
  79. The hidden third: improving outcome in treatment-resistant depression
  80. Preface
  81. The development of deep brain stimulation for neurological and psychiatric disorders: clinical, societal and ethical issues
  82. Brain stimulation therapies for neuropsychiatric disease
  83. Toward an Emergent Consensus–International Perspectives on Neuroethics of Deep Brain Stimulation for Psychiatric Disorders–A Tower of Babel?
  84. How Happy Is Too Happy? Euphoria, Neuroethics, and Deep Brain Stimulation of the Nucleus Accumbens
  85. Panksepp’s SEEKING System Concepts and Their Implications for the Treatment of Depression with Deep-Brain Stimulation
  86. Diffusion Tensor Imaging and Neuromodulation
  87. Hirnstimulationsverfahren
  88. Bipolare Störungen (ICD-10 F3)
  89. Hirnstimulationsverfahren
  90. Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance
  91. Faculty of 1000 evaluation for Somatic treatments for mood disorders.
  92. Cross-species affective functions of the medial forebrain bundle—Implications for the treatment of affective pain and depression in humans
  93. Carotid atherosclerosis in depression and anxiety: Associations for age of depression onset
  94. Neuropsychological safety of nucleus accumbens deep brain stimulation for major depression: Effects of 12-month stimulation
  95. FDA Exemptions: The Authors Reply
  96. Humanitarian Device Exemptions: The Authors Reply
  97. Overnight deprivation from smoking disrupts amygdala responses to fear
  98. Ethical guidance for the management of conflicts of interest for researchers, engineers and clinicians engaged in the development of therapeutic deep brain stimulation
  99. Antidepressant effects, of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depression
  100. Depression comorbidity in spinocerebellar ataxia
  101. Chronic vagus nerve stimulation for treatment-resistant depression increases regional cerebral blood flow in the dorsolateral prefrontal cortex
  102. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response
  103. Misuse Of The FDA's Humanitarian Device Exemption In Deep Brain Stimulation For Obsessive-Compulsive Disorder
  104. Modulating Affect, Cognition, and Behavior – Prospects of Deep Brain Stimulation for Treatment-Resistant Psychiatric Disorders
  105. Electrodes in the brain—Ethical criteria for research and treatment with deep brain stimulation for neuropsychiatric disorders
  106. Pegylated human interferon alpha 2a does not induce depression-associated changes in mice
  107. Faculty of 1000 evaluation for Illness risk following rapid versus gradual discontinuation of antidepressants.
  108. Registering Findings From Deep Brain Stimulation—Reply
  109. The N-Methyl-D-Aspartate Receptor Co-agonist D-Cycloserine Facilitates Declarative Learning and Hippocampal Activity in Humans
  110. Two-Year Outcome of Vagus Nerve Stimulation in Treatment-Resistant Depression
  111. Die Entwicklung der tiefen Hirnstimulation bei der Behandlung therapieresistenter psychiatrischer Erkrankungen
  112. Deep Brain Stimulation and the Neuroethics of Responsible Publishing
  113. Electrodes in the brain—Ethical criteria for research and treatment with deep brain stimulation for neuropsychiatric disorders
  114. Intracranial EEG Correlates of Expectancy and Memory Formation in the Human Hippocampus and Nucleus Accumbens
  115. Neuromodulation – ECT, rTMS, DBS
  116. WFSBP Guidelines on Brain Stimulation Treatments in Psychiatry
  117. Nucleus Accumbens Deep Brain Stimulation Decreases Ratings of Depression and Anxiety in Treatment-Resistant Depression
  118. Tiefe Hirnstimulation bei Depression
  119. FDA Considers Classification of ECT
  120. Stimulationstherapien bei affektiven Störungen jenseits der EKT
  121. Scientific and Ethical Issues Related to Deep Brain Stimulation for Disorders of Mood, Behavior, and Thought
  122. Can we use magnetic/electric fields to help in treatment-resistant depression?
  123. Nuclei Accumbens Phase Synchrony Predicts Decision-Making Reversals Following Negative Feedback
  124. Magnetic Seizure Therapy of Treatment-Resistant Depression in a Patient With Bipolar Disorder
  125. Good Vibrations: Cross-frequency Coupling in the Human Nucleus Accumbens during Reward Processing
  126. Psychiatrische Indikationen für die tiefe Hirnstimulation
  127. Baseline severity of depression predicts antidepressant drug response relative to escitalopram
  128. Deep brain stimulation: Methods, indications, locations, and efficacy
  129. Noradrenergic enhancement of amygdala responses to fear
  130. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD)
  131. WFSBP Guidelines on Brain Stimulation Treatments in Psychiatry
  132. Controversy: Repetitive transcranial magnetic stimulation or transcranial direct current stimulation shows efficacy in treating psychiatric diseases (depression, mania, schizophrenia, obsessive-complusive disorder, panic, posttraumatic stress disorder)
  133. Clozapine: Acquittal of the usual suspect
  134. Bipolare Störungen (ICD-10 F3)
  135. Deep brain stimulation for psychiatric disorders — state of the art
  136. Neuroelectric Signatures of Reward Learning and Decision-Making in the Human Nucleus Accumbens
  137. Stimulating personality: Ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes
  138. Modeling a Negative Response Bias in the Human Amygdala by Noradrenergic-Glucocorticoid Interactions
  139. Reduced 5-HT2Areceptor signaling following selective bilateral amygdala damage
  140. P.2.a.003 Baseline severity of depression predicts antidepressant drug response
  141. Corrigendum
  142. Cerebral blood flow effects of acute intravenous heroin administration
  143. Vagus nerve stimulation for depression: efficacy and safety in a European study
  144. Pattern of regional cerebral blood-flow changes induced by acute heroin administration – a perfusion MRI study
  145. Mood improvement after deep brain stimulation of the internal globus pallidus for tardive dyskinesia in a patient suffering from major depression
  146. Hirnstimulationsverfahren bei Therapieresistenz
  147. Deep Brain Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major Depression
  148. Bipolare Störungen (ICD-10 F3)
  149. Deep-Brain Stimulation for Parkinson's Disease
  150. Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex affects divided attention immediately after cessation of stimulation
  151. IV.9 Epidemiology of major depression - how is the view changing?
  152. Repetitive transcranial magnetic stimulation (rTMS) in depression
  153. Bipolare Störungen (ICD-10 F3)
  154. C.12.02 Is depression neurodegenerative?
  155. S.18.04 Repetitive transcranial magnetic stimulation (TMS)
  156. Deep brain stimulation for treatment of refractory depression
  157. ECT and rTMS for depression
  158. Incident Mania During Therapy With Vagus Nerve Stimulation
  159. Decreased frontal white-matter volume in chronic substance abuse
  160. Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression
  161. Brain Stimulation in Depression
  162. Cognitive Improvement in Schizophrenic Patients does not Require a Serotonergic Mechanism: Randomized Controlled Trial of Olanzapine vs Amisulpride
  163. Learning From the History of Neuroscience: Dogma and Patient Interests
  164. Induced Seizures as Psychiatric Therapy
  165. Erratum: Diminished GABAA Receptor Binding Capacity and a DNA Base Substitution in a Patient with Treatment-Resistant Depression and Anxiety
  166. Erratum: Diminished GABAA Receptor Binding Capacity and a DNA Base Substitution in a Patient with Treatment-Resistant Depression and Anxiety
  167. Repetitive transcranial magnetic stimulation: a putative add-on treatment for major depression in elderly patients
  168. Novel physical treatments for major depression: vagus nerve stimulation, transcranial magnetic stimulation and magnetic seizure therapy
  169. Transkranielle Magnetstimulation
  170. Diminished GABAA Receptor-Binding Capacity and a DNA Base Substitution in a Patient with Treatment-Resistant Depression and Anxiety
  171. Magnetic Seizure Therapy Improves Mood in Refractory Major Depression
  172. Progress in Therapeutic Brain Stimulation in Neuropsychiatry
  173. Repetitive transcranial magnetic stimulation for the treatment of depression
  174. Safety and Feasibility of Magnetic Seizure Therapy (MST) in Major Depression: Randomized Within-Subject Comparison with Electroconvulsive Therapy
  175. Transcranial magnetic stimulation
  176. Perspectives for New Pharmacological Treatments of Alcoholism and Substance Dependence
  177. Physical Treatments
  178. Mechanisms and State of the Art of Vagus Nerve Stimulation
  179. Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Affective Disorders
  180. Heteromodal association cortex involvement in schizophrenia
  181. An overview of the antidepressant properties of transcranial magnetic stimulation
  182. Magnetic seizure induction for the treatment of major depression
  183. Transcranial magnetic stimulation for treating depression
  184. Hemispheric asymmetry in visuospatial attention assessed with transcranial magnetic stimulation
  185. Cerebral blood flow in obsessive–compulsive patients with major depression: effect of treatment with sertraline or desipramine on treatment responders and non-responders
  186. Double‐pulse transcranial magnetic stimulation over the frontal eye field facilitates triggering of memory‐guided saccades
  187. High frequency repetitive transcranial magnetic stimulation (rTMS) of the left dorsolateral cortex: EEG topography during waking and subsequent sleep
  188. Nichtorganische Störungen in der Ophthalmologie: Übersicht der Diagnostik und Therapie1
  189. Magnetic Seizure Therapy of Major Depression
  190. S23.01 Changes in gene expression during TMS
  191. SPECT imaging of drug effects in humans
  192. Mood effects of repetitive transcranial magnetic stimulation of left prefrontal cortex in healthy volunteers
  193. Structural and functional effects of chronic alcohol abuse on the brain
  194. Repetitive transcranial magnetic stimulation activates specific regions in rat brain
  195. SPECT brain blood flow changes with continuous ligand infusion during previously-learned WCST performance
  196. PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects
  197. Sex Differences in Schizophrenia
  198. Exploratory factor analysis of MRI brain structure measures in schizophrenia
  199. rCBF changes in OCD patients receiving antidepressants
  200. Pitfalls of SPECT Studies of Acute Ethanol-Induced Changes in Cerebral Blood Flow
  201. Structural differences in the cerebral cortex of healthy female and male subjects: a magnetic resonance imaging study
  202. Heteromodal association cortex in schizophrenia
  203. Suicide reporting in the Swiss print media
  204. The involvement of benzodiazepine receptor ligands in hepatic encephalopathy
  205. Detection of benzodiazepine-like activity in hepatic encephalopathy requires an initial lipophilic extraction procedure!
  206. Reply
  207. Decreased regional cortical gray matter volume in schizophrenia
  208. Magnetic resonance imaging evaluation of the effects of ageing on grey–white ratio in the human brain
  209. Increased benzodiazepine-like activity is neither necessary nor sufficient to explain acute hepatic encephalopathy in the thioacetamide-treated rat
  210. Paradoxical effects of mild hypoxia and moderate altitude on human visual perception
  211. Depressive Erkrankungen
  212. Vagusnervstimulation
  213. Faculty of 1000 evaluation for Linking molecules to mood: new insight into the biology of depression.
  214. Faculty of 1000 evaluation for Deep brain stimulation (DBS) at the interface of neurology and psychiatry.
  215. Faculty of 1000 evaluation for DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses.
  216. Faculty of 1000 evaluation for Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial.
  217. Faculty of 1000 evaluation for A Randomized Sham-Controlled Trial of DBS of the VC/VS for Treatment-Resistant Depression